These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33176943)

  • 1. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
    Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
    Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Optimization of Ergosterol Peroxide Derivatives as Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer.
    Luo R; Zhao H; Deng S; Wu J; Wang H; Guo X; Han C; Ren W; Han Y; Zhou J; Lin Y; Bu M
    Molecules; 2024 Sep; 29(18):. PubMed ID: 39339370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of novel withangulatin A derivatives as potential anticancer agents.
    Zhou WX; Chen C; Liu XQ; Li Y; Kong LY; Luo JG
    Bioorg Chem; 2021 Mar; 108():104690. PubMed ID: 33592485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.
    Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L
    Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
    Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
    Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery".
    Fan Y; Si H; Zhang Z; Zhong L; Sun H; Zhu C; Yin Z; Li H; Tang G; Yao SQ; Sun P; Zhang ZM; Ding K; Li Z
    J Med Chem; 2021 Nov; 64(21):15582-15592. PubMed ID: 34623802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
    Xu X; Wang J; Wang M; Yuan X; Li L; Zhang C; Huang H; Jing T; Wang C; Tong C; Zhou L; Meng Y; Xu P; Kou J; Qiu Z; Li Z; Bian J
    J Med Chem; 2021 Apr; 64(8):4588-4611. PubMed ID: 33792311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents.
    Luo Y; Wu W; Zha D; Zhou W; Wang C; Huang J; Chen S; Yu L; Li Y; Huang Q; Zhang J; Zhang C
    Bioorg Med Chem Lett; 2021 Sep; 47():128230. PubMed ID: 34186178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
    Shen LW; Jiang XX; Li ZQ; Li J; Wang M; Jia GF; Ding X; Lei L; Gong QH; Gao N
    Acta Pharmacol Sin; 2022 Jan; 43(1):177-193. PubMed ID: 34294886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring potential molecular targets and therapeutic efficacy of beauvericin in triple-negative breast cancer cells.
    Patra A; Ghosh SS; Saini GK
    Comput Biol Chem; 2024 Oct; 112():108154. PubMed ID: 39029290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer
    Gao Z; Wang T; Li R; Du Y; Lv H; Zhang L; Chen H; Shi X; Li Q; Shen J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):125-134. PubMed ID: 34894977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
    Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
    J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer.
    Chen L; Long C; Nguyen J; Kumar D; Lee J
    Bioorg Med Chem Lett; 2018 Feb; 28(3):420-424. PubMed ID: 29287960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
    Jinih M; Wang JH; Pfirrmann RW; O'Leary DP; Corrigan MA; Redmond HP
    Anticancer Res; 2021 May; 41(5):2247-2256. PubMed ID: 33952451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sophoridine Derivatives Induce Apoptosis and Autophagy to Suppress the Growth of Triple-Negative Breast Cancer through Inhibition of mTOR Signaling.
    Dai L; Wang L; Tan C; Cai J; Shen H; Zhang T; Zhi S; Yang Z; Hu Y; Zhao X; Li D
    ChemMedChem; 2022 Jan; 17(1):e202100434. PubMed ID: 34569159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of chalcone acetamide derivatives against triple negative breast cancer.
    Kumar P; Singh R; Sharma D; Hassan QP; Gopu B; Anal JMH
    Bioorg Med Chem Lett; 2024 Jul; 107():129795. PubMed ID: 38750906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.